TScan Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gavin MacBeath
- Full Time Employees
- 138
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 830 Winter Street Waltham MA United States of America 02451
- IPO Date
- Jul 16, 2021
- CIK
- 0001783328
- Website
- tscan.com
- Similar Companies
- Business
- TScan Therapeutics, Inc. TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company that develops T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The company offers lead product candidates TSC-100 and TSC-101 targeting hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation (HCT); multiplex TCR-T therapies including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for solid tumors through its ImmunoBank platform to address tumor heterogeneity and antigen escape; and preclinical programs in autoimmunity and infectious diseases leveraging its proprietary TargetScan platform for T cell target discovery. TScan Therapeutics operates primarily in the United States with research and development focused on oncology, serving patients undergoing HCT and those with advanced solid tumors. Founded in early 2018 and headquartered in Waltham, Massachusetts, the company maintains facilities at 830 Winter Street and 880 Winter Street for laboratory and office space. Recent developments include reaching agreement with the U.S. Food and Drug Administration (FDA) in October 2025 on a pivotal trial design for TSC-101 mirroring the ongoing ALLOHA Phase 1 trial, with plans to initiate the registrational study in the second quarter of 2026 and present two-year relapse-free data at the American Society of Hematology meeting on December 6, 2025; pausing further enrollment in the PLEXI-T solid tumor Phase 1 trial (NCT05973487) in early November 2025 to prioritize the hematologic malignancies program and advance preclinical in vivo engineering for solid tumors; implementing a commercial-ready manufacturing process that reduces production time by five days; planning investigational new drug (IND) applications for two additional TCR-T candidates to expand HLA coverage in the fourth quarter of 2025; dosing the first patients with multiplex TCR-T therapy in the PLEXI-T trial earlier in 2025; and maintaining collaborations with Amgen Inc. for target discovery in Crohn's disease, initiated in May 2023 with potential milestone payments exceeding $500 million, following an earlier alliance with Novartis Institutes for BioMedical Research, Inc. that concluded in March 2024. As of September 30, 2025, TScan Therapeutics holds cash, cash equivalents, and marketable securities of $184.5 million, sufficient to fund operations into the second half of 2027.
Company News
Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX)
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages